ES2148174T3 - Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. - Google Patents

Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.

Info

Publication number
ES2148174T3
ES2148174T3 ES92907704T ES92907704T ES2148174T3 ES 2148174 T3 ES2148174 T3 ES 2148174T3 ES 92907704 T ES92907704 T ES 92907704T ES 92907704 T ES92907704 T ES 92907704T ES 2148174 T3 ES2148174 T3 ES 2148174T3
Authority
ES
Spain
Prior art keywords
receptor antagonist
opiacean
hypercinetic
modulates
movement disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907704T
Other languages
English (en)
Inventor
Conan Kornetsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Application granted granted Critical
Publication of ES2148174T3 publication Critical patent/ES2148174T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN METODO PARA MODULAR EL ACCESO DE DISQUINESIA TARDIA EN UN SUJETO, INCLUYE EL PASO DE ADMINISTRAR AL SUJETO UN ANTAGONISTA RECEPTOR NARCOTICO CONJUNTAMENTE CON EL NEUROLEPTICO. UN METODO PARA MODULAR UN DESORDEN DE MOVIMIENTO HIPERCINETICO PSICOGENICO, GENETICO O IDIOPATICO, TAL COMO SON LAS CARACTERISTICAS DE LA ENFERMEDAD DE HUNTINGTON''S, INCLUYE EL PASO DE ADMINISTRAR AL SUJETO UN ANTAGONISTA RECEPTOR NARCOTICO.
ES92907704T 1991-02-25 1992-02-25 Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. Expired - Lifetime ES2148174T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66054391A 1991-02-25 1991-02-25

Publications (1)

Publication Number Publication Date
ES2148174T3 true ES2148174T3 (es) 2000-10-16

Family

ID=24649948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907704T Expired - Lifetime ES2148174T3 (es) 1991-02-25 1992-02-25 Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.

Country Status (9)

Country Link
US (1) US6153620A (es)
EP (1) EP0573565B1 (es)
JP (1) JPH06505747A (es)
AT (1) ATE194753T1 (es)
AU (1) AU658401B2 (es)
CA (1) CA2104229C (es)
DE (1) DE69231274T2 (es)
ES (1) ES2148174T3 (es)
WO (1) WO1992014364A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
PL2151240T3 (pl) * 2007-04-24 2014-01-31 Toray Industries Środek terapeutyczny lub profilaktyczny przeciw dyskinezie
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
GB2543271A (en) * 2015-10-12 2017-04-19 Lars Holger Hermann Dr Products for treating psychogenic pain disorders

Also Published As

Publication number Publication date
CA2104229A1 (en) 1992-08-26
US6153620A (en) 2000-11-28
EP0573565A1 (en) 1993-12-15
EP0573565B1 (en) 2000-07-19
AU658401B2 (en) 1995-04-13
CA2104229C (en) 1997-04-15
WO1992014364A1 (en) 1992-09-03
JPH06505747A (ja) 1994-06-30
DE69231274D1 (de) 2000-08-24
EP0573565A4 (en) 1994-03-18
DE69231274T2 (de) 2000-11-30
ATE194753T1 (de) 2000-08-15
AU1456392A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
ES2148174T3 (es) Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos.
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
NO305603B1 (no) 2,6-diaminopurin-derivater, anvendelse derav samt farmas°ytisk blanding
AP9400666A0 (en) Benzofuran derivatives.
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
PT817847E (pt) Receptor de il-17
FI920217L (fi) Angiotensin ii receptor blockerande 2,3,6-substituerade kinazolinoner.
EP0691037A4 (en) ELECTROCHEMICAL FILLER SYSTEM
ITRM930561A0 (it) Classificatore purificatore polverizzatore di carbone.
EP0606804A3 (en) Neurotensin receptor marker.
BR9814127A (pt) Nova forma de dosagem oral para carvedilol
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
EP0625591A3 (en) Electrolyzer.
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.
FR2719929B1 (fr) Dispositif de substitution d'une image artificielle présentée à un pilote d'aéronef par l'image réelle correspondante.
ES2052105T3 (es) Gilanteno: principio anti-metastasico de sanguijuela de america del sur haementaria ghilianii.
ATE227122T1 (de) Stabilisierte tablettenformulierung
EA199700449A1 (ru) Способ предотвращения остеопороза
FR2698482B1 (fr) Dispositif générateur d'images par effet de luminescence.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
BR9805251A (pt) Veículo.
FR2712321B1 (fr) Urinoir d'un nouveau type.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573565

Country of ref document: ES